NZ592741A - Thiochromene derivatives as hif hydroxylase inhibitors - Google Patents
Thiochromene derivatives as hif hydroxylase inhibitorsInfo
- Publication number
- NZ592741A NZ592741A NZ592741A NZ59274109A NZ592741A NZ 592741 A NZ592741 A NZ 592741A NZ 592741 A NZ592741 A NZ 592741A NZ 59274109 A NZ59274109 A NZ 59274109A NZ 592741 A NZ592741 A NZ 592741A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- formula
- hif
- disclosed
- thiochromene
- Prior art date
Links
- 102000008109 Mixed Function Oxygenases Human genes 0.000 title abstract 3
- 108010074633 Mixed Function Oxygenases Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000005076 thiochromenes Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- VWWZZNKIUJELAD-UHFFFAOYSA-N OC1=C(C(=O)NCC(O)=O)C(=O)SC2=CC(OC)=CC=C21 Chemical compound OC1=C(C(=O)NCC(O)=O)C(=O)SC2=CC(OC)=CC=C21 VWWZZNKIUJELAD-UHFFFAOYSA-N 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 230000007954 hypoxia Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11497108P | 2008-11-14 | 2008-11-14 | |
| PCT/US2009/064065 WO2010056767A1 (en) | 2008-11-14 | 2009-11-11 | Thiochromene derivatives as hip hydroxylase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ592741A true NZ592741A (en) | 2013-03-28 |
Family
ID=41698287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ592741A NZ592741A (en) | 2008-11-14 | 2009-11-11 | Thiochromene derivatives as hif hydroxylase inhibitors |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8927591B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2370422B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5649584B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN105037323A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009314155B2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL212762A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ592741A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010056767A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| NZ543448A (en) | 2003-06-06 | 2009-02-28 | Fibrogen Inc | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| CN105037323A (zh) | 2008-11-14 | 2015-11-11 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| ES2893699T3 (es) | 2010-03-31 | 2022-02-09 | Scripps Research Inst | Reprogramación de células |
| EP2465841A1 (en) * | 2010-11-19 | 2012-06-20 | Lonza Ltd. | Preparation of esters of mono- or dicarboxylic non-aromatic and aromatic acids |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| GB201102659D0 (en) | 2011-02-15 | 2011-03-30 | Isis Innovation | Assay |
| NO2686520T3 (cg-RX-API-DMAC7.html) | 2011-06-06 | 2018-03-17 | ||
| GB201113101D0 (en) | 2011-07-28 | 2011-09-14 | Isis Innovation | Assay |
| NZ700760A (en) | 2012-03-09 | 2016-08-26 | Fibrogen Inc | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| EP2872487B1 (en) | 2012-07-16 | 2017-04-26 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| CN115093370A (zh) | 2012-07-16 | 2022-09-23 | 菲布罗根有限公司 | 脯氨酰羟化酶抑制剂的晶体形态 |
| MX2015016536A (es) | 2013-06-06 | 2016-08-11 | Fibrogen Inc | Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif. |
| MY204336A (en) | 2013-06-13 | 2024-08-23 | Akebia Therapeutics Inc | Compositions and methods for treating anemia |
| EP3190104B1 (en) | 2014-09-02 | 2021-10-27 | Sunshine Lake Pharma Co., Ltd. | Quinolinone compound and use thereof |
| AU2016209126A1 (en) | 2015-01-23 | 2017-08-10 | Akebia Therapeutics, Inc. | Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof |
| AU2016235534A1 (en) * | 2015-03-20 | 2017-10-12 | Akebia Therapeutics, Inc. | Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors |
| UA123308C2 (uk) | 2015-04-01 | 2021-03-17 | Екебіа Терапьютікс, Інк. | Композиції і способи для лікування анемії |
| US11021478B2 (en) | 2017-05-09 | 2021-06-01 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| MX2020011845A (es) | 2018-05-09 | 2021-01-15 | Akebia Therapeutics Inc | Proceso para preparar acido 2-[[5-(3-clorofenil)-3-hidroxipiridina -2-carbonil]amino]acetico. |
| EP4138825A1 (en) | 2020-04-20 | 2023-03-01 | Akebia Therapeutics Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| WO2022251563A1 (en) | 2021-05-27 | 2022-12-01 | Keryx Biopharmaceuticals, Inc. | Pediatric formulations of ferric citrate |
| CN115944626B (zh) * | 2022-12-08 | 2024-04-19 | 桂林医学院附属医院 | 小分子化合物在制备抗缺氧或缺血再灌注损伤药物中的应用 |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036964A (en) | 1973-10-11 | 1977-07-19 | Beecham Group Limited | Isocarbostyril-3-carboxylic acid derivatives for the prophylaxis of asthma, hayfever and rhinitis |
| US3989704A (en) | 1973-10-30 | 1976-11-02 | Sandoz, Inc. | 3-Substituted-4-aryl isoquinolines |
| GB1582217A (en) | 1978-02-27 | 1981-01-07 | Teijin Ltd | Penicillin derivatives medicines containing the same and process for producing the same |
| DE2818423A1 (de) | 1978-04-27 | 1979-11-08 | Hoechst Ag | Neue isochinolinderivate und verfahren zu ihrer herstellung |
| DE3233424A1 (de) | 1982-09-09 | 1984-03-15 | Hoechst Ag, 6230 Frankfurt | Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| US4559403A (en) | 1983-05-19 | 1985-12-17 | Hoffmann-La Roche Inc. | Substituted isoquinolines |
| FR2562893B1 (fr) * | 1984-04-12 | 1986-06-27 | Lipha | Derives de l'hydroxy-4-2h-1-benzothiopyran-2-one, leurs preparations et applications dans le domaine rodenticide |
| US4584379A (en) | 1985-01-22 | 1986-04-22 | Merrell Dow Pharmaceuticals Inc. | Isoquinoline thromboxane synthetase inhibitors |
| US4822800A (en) | 1986-06-09 | 1989-04-18 | Ortho Pharmaceutical Corporation | Isoquinolinol compounds having cardiotonic and phosphodiesterase fraction III inhibiting properties and/or renal vasodilating properties |
| GB8816519D0 (en) | 1987-07-23 | 1988-08-17 | Ici Plc | Antibiotic compounds |
| US4952588A (en) | 1987-11-27 | 1990-08-28 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinoline-and 1-aryl-3-isoquinoline-carboxamides |
| US4966906A (en) | 1987-11-27 | 1990-10-30 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-isoquinolinecarboxamides |
| EP0532466A3 (en) | 1991-09-12 | 1993-06-16 | Ciba-Geigy Ag | Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use |
| US5378720A (en) | 1991-12-19 | 1995-01-03 | Sterling Winthrop Inc. | Saccharin derivative proteolytic enzyme inhibitors |
| EP0626178A1 (de) | 1993-05-17 | 1994-11-30 | Ciba-Geigy Ag | Verwendung von Hemmstoffen von HIV-Aspartatproteasen zur Bekämpfung von Tumorerkrankungen |
| ES2101421T3 (es) | 1993-11-02 | 1997-07-01 | Hoechst Ag | Amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos. |
| EP0650960B1 (de) | 1993-11-02 | 1997-03-05 | Hoechst Aktiengesellschaft | Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel |
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| US5563143A (en) | 1994-09-21 | 1996-10-08 | Pfizer Inc. | Catechol diether compounds as inhibitors of TNF release |
| AU4515696A (en) | 1994-12-12 | 1996-07-03 | Merck & Co., Inc. | Substituted 2-aminopyridines as inhibitors of nitric oxide synthase |
| US5741657A (en) | 1995-03-20 | 1998-04-21 | The Regents Of The University Of California | Fluorogenic substrates for β-lactamase and methods of use |
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| US5955604A (en) | 1996-10-15 | 1999-09-21 | The Regents Of The University Of California | Substrates for β-lactamase and uses thereof |
| AU5362998A (en) | 1996-11-27 | 1998-06-22 | Du Pont Pharmaceuticals Company | Novel integrin receptor antagonists |
| JP4074683B2 (ja) * | 1997-03-31 | 2008-04-09 | 富士フイルム株式会社 | ベンゾピラン化合物の製造方法 |
| GB9707830D0 (en) | 1997-04-18 | 1997-06-04 | Smithkline Beecham Plc | Novel compounds |
| AU7526798A (en) | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| DE19746287A1 (de) | 1997-10-20 | 1999-04-22 | Hoechst Marion Roussel De Gmbh | Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel |
| FR2779963A1 (fr) | 1998-06-22 | 1999-12-24 | Centre Nat Rech Scient | Utilisation d'un compose possedant une affinite pour le recepteur mitochondrial des benzodiazepines en therapie du cancer |
| IT1302677B1 (it) | 1998-10-15 | 2000-09-29 | Zambon Spa | Derivati benzazinici inibitori della fosfodiesterasi 4 |
| AU4802500A (en) | 1999-04-26 | 2000-11-10 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
| IT1320162B1 (it) | 2000-02-09 | 2003-11-18 | Rotta Research Lab | Derivati della tirosina ad attivita' anti leucotrienica, procedimentoper la loro preparazione e loro uso farmaceutico. |
| US7622503B2 (en) | 2000-08-24 | 2009-11-24 | University Of Tennessee Research Foundation | Selective androgen receptor modulators and methods of use thereof |
| FI20002044A0 (fi) | 2000-09-15 | 2000-09-15 | Orion Yhtymae Oyj | Comt-entsyymiä estäviä naftaleenijohdannaisia |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| EP1379630B1 (en) | 2001-03-21 | 2012-09-26 | Isis Innovation Limited | Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase |
| WO2002100832A1 (en) | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc. | Isoquinoline compounds having antiinfective activity |
| WO2002101073A2 (en) | 2001-06-13 | 2002-12-19 | Genesoft Pharmaceuticals, Inc. | Aryl-benzimidazole compounds having antiinfective activity |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US7294457B2 (en) | 2001-08-07 | 2007-11-13 | Boehringer Ingelheim (Canada) Ltd. | Direct binding assay for identifying inhibitors of HCV polymerase |
| US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
| US20030176317A1 (en) | 2001-12-06 | 2003-09-18 | Volkmar Guenzler-Pukall | Stabilization of hypoxia inducible factor (HIF) alpha |
| GB0206711D0 (en) | 2002-03-21 | 2002-05-01 | Isis Innovation | HIF Inhibitor |
| CN1506359A (zh) | 2002-12-05 | 2004-06-23 | �й�ҽѧ��ѧԺҩ���о��� | 新的香豆素酰胺衍生物及其制法和其药物组合物与用途 |
| US8124582B2 (en) | 2002-12-06 | 2012-02-28 | Fibrogen, Inc. | Treatment of diabetes |
| US7618940B2 (en) | 2002-12-06 | 2009-11-17 | Fibrogen, Inc. | Fat regulation |
| WO2005007192A2 (en) | 2003-06-06 | 2005-01-27 | Fibrogen, Inc. | Cytoprotection through the use of hif hydroxylase inhibitors |
| US8614204B2 (en) | 2003-06-06 | 2013-12-24 | Fibrogen, Inc. | Enhanced erythropoiesis and iron metabolism |
| NZ543448A (en) | 2003-06-06 | 2009-02-28 | Fibrogen Inc | Nitrogen-containing heteroaryl compounds and their use in increasing endogeneous erythropoietin |
| AU2004259675A1 (en) | 2003-07-15 | 2005-02-03 | Merck & Co., Inc. | Hydroxypyridine CGRP receptor antagonists |
| WO2005011696A1 (en) | 2003-08-01 | 2005-02-10 | Fibrogen, Inc. | Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers |
| US7208601B2 (en) | 2003-08-08 | 2007-04-24 | Mjalli Adnan M M | Aryl and heteroaryl compounds, compositions, and methods of use |
| EP1660439A2 (en) | 2003-08-08 | 2006-05-31 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| US7304168B2 (en) | 2003-08-14 | 2007-12-04 | Board Of Regents, University Of Texas System | Photo-caged fluorescent molecules |
| JP2007522225A (ja) | 2004-02-10 | 2007-08-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ａ４インテグリン拮抗薬としてのピリダジノン |
| US7248053B2 (en) | 2004-07-15 | 2007-07-24 | Powerprecise Solutions, Inc. | One time operating state detecting method and apparatus |
| EP1676834A1 (en) | 2004-12-30 | 2006-07-05 | Sanofi-Aventis Deutschland GmbH | Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation |
| US8703795B2 (en) | 2005-03-02 | 2014-04-22 | Fibrogen, Inc. | Thienopyridine compounds, and methods of use thereof |
| JP5390184B2 (ja) | 2005-06-06 | 2014-01-15 | ファイブローゲン、インコーポレーテッド | 貧血の改良された治療方法 |
| CN101242817B (zh) | 2005-06-15 | 2016-08-31 | 菲布罗根公司 | HIF1α调节剂在治疗癌症中的用途 |
| CA2618770A1 (en) | 2005-08-25 | 2007-03-01 | Emory University | Hif inhibitors |
| WO2007038571A2 (en) | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| ES2897529T3 (es) | 2005-12-01 | 2022-03-01 | Nuevolution As | Métodos de codificación enzimática para la síntesis eficiente de bibliotecas grandes |
| ES2446416T3 (es) | 2005-12-09 | 2014-03-07 | Amgen, Inc. | Compuestos basados en quinolona que presentan actividad inhibidora de prolil hidroxilasa, composiciones y usos de los mismos |
| AU2007211077B2 (en) * | 2006-01-27 | 2012-09-20 | Fibrogen, Inc. | Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (HIF) |
| AR059733A1 (es) * | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| MX2008012734A (es) | 2006-04-04 | 2009-01-29 | Fibrogen Inc | Compuestos pirrolo- y tiazolo-piridina como moduladores del factor inducible de hipoxia (hif). |
| WO2007136990A2 (en) | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| US7713986B2 (en) | 2006-06-15 | 2010-05-11 | Fibrogen, Inc. | Compounds and methods for treatment of chemotherapy-induced anemia |
| US20070293575A1 (en) | 2006-06-15 | 2007-12-20 | Fibrogen, Inc. | Compounds and methods for treatment of cancer-related anemia |
| TWI394747B (zh) | 2006-06-23 | 2013-05-01 | Smithkline Beecham Corp | 脯胺醯基羥化酶抑制劑 |
| AU2007334321B2 (en) | 2006-12-18 | 2012-03-08 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| WO2008076427A2 (en) * | 2006-12-18 | 2008-06-26 | Amgen Inc. | Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| TW200845994A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: prolyl hydroxylase inhibitors |
| TW200845991A (en) | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| EP2155680B1 (en) | 2007-04-18 | 2013-12-04 | Amgen, Inc | Indanone derivatives that inhibit prolyl hydroxylase |
| CA2683758A1 (en) * | 2007-04-18 | 2008-10-30 | Merck & Co., Inc. | Novel 1,8-naphthyridine compounds |
| JP2010524942A (ja) | 2007-04-18 | 2010-07-22 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼを阻害するキノロン及びアザキノロン |
| CA2685216C (en) | 2007-05-04 | 2014-07-08 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| WO2008137084A2 (en) | 2007-05-04 | 2008-11-13 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| WO2009039322A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039321A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009039323A1 (en) | 2007-09-19 | 2009-03-26 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| WO2009070644A1 (en) | 2007-11-30 | 2009-06-04 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| JP2011508725A (ja) | 2007-11-30 | 2011-03-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| WO2009073669A1 (en) | 2007-12-03 | 2009-06-11 | Fibrogen, Inc. | Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions |
| EP2227232A1 (en) | 2007-12-07 | 2010-09-15 | Fibrogen, Inc. | Methods for inhibiting t helper cell differentiation |
| US20110039879A1 (en) * | 2007-12-07 | 2011-02-17 | FibroGen ,Inc. | Methods for increasing white blood cells |
| JP2011507894A (ja) | 2007-12-19 | 2011-03-10 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| US8952160B2 (en) | 2008-01-11 | 2015-02-10 | Fibrogen, Inc. | Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity |
| WO2009100250A1 (en) | 2008-02-05 | 2009-08-13 | Fibrogen, Inc. | Chromene derivatives and use thereof as hif hydroxylase activity inhibitors |
| EP2334682B1 (en) | 2008-08-20 | 2017-10-04 | Fibrogen, Inc. | Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| CN105037323A (zh) | 2008-11-14 | 2015-11-11 | 菲布罗根有限公司 | 作为hif羟化酶抑制剂的苯并噻喃衍生物 |
| CN103608346B (zh) | 2011-02-02 | 2016-06-15 | 菲布罗根有限公司 | 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物 |
| NZ700760A (en) | 2012-03-09 | 2016-08-26 | Fibrogen Inc | 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors |
| US8883823B2 (en) | 2012-07-16 | 2014-11-11 | Fibrogen, Inc. | Crystalline forms of a prolyl hydroxylase inhibitor |
| CN115093370A (zh) | 2012-07-16 | 2022-09-23 | 菲布罗根有限公司 | 脯氨酰羟化酶抑制剂的晶体形态 |
| EP2872487B1 (en) | 2012-07-16 | 2017-04-26 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| MX360048B (es) | 2013-01-24 | 2018-10-19 | Fibrogen Inc | Formas cristalinas de acido { [1-ciano-5-(4-clorofenoxi)-4-hidroxi -isoquinolin-3-carbonil]-amino}-acetico. |
| MX2015016536A (es) | 2013-06-06 | 2016-08-11 | Fibrogen Inc | Formulaciones farmacéuticas de un inhibidor de hidroxilasa de hif. |
-
2009
- 2009-11-11 CN CN201510259787.8A patent/CN105037323A/zh active Pending
- 2009-11-11 WO PCT/US2009/064065 patent/WO2010056767A1/en not_active Ceased
- 2009-11-11 JP JP2011536447A patent/JP5649584B2/ja not_active Expired - Fee Related
- 2009-11-11 US US13/128,620 patent/US8927591B2/en active Active
- 2009-11-11 EP EP09756097.3A patent/EP2370422B1/en active Active
- 2009-11-11 AU AU2009314155A patent/AU2009314155B2/en not_active Ceased
- 2009-11-11 NZ NZ592741A patent/NZ592741A/xx not_active IP Right Cessation
- 2009-11-11 CN CN200980154106.4A patent/CN102272117B/zh not_active Expired - Fee Related
-
2011
- 2011-05-08 IL IL212762A patent/IL212762A/en active IP Right Grant
-
2014
- 2014-12-24 US US14/582,914 patent/US9149476B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012508752A (ja) | 2012-04-12 |
| CN102272117B (zh) | 2015-06-17 |
| AU2009314155A1 (en) | 2010-05-20 |
| US8927591B2 (en) | 2015-01-06 |
| AU2009314155B2 (en) | 2015-10-08 |
| EP2370422A1 (en) | 2011-10-05 |
| CN102272117A (zh) | 2011-12-07 |
| IL212762A (en) | 2017-09-28 |
| US20110305776A1 (en) | 2011-12-15 |
| JP5649584B2 (ja) | 2015-01-07 |
| US9149476B2 (en) | 2015-10-06 |
| IL212762A0 (en) | 2011-07-31 |
| EP2370422B1 (en) | 2019-06-05 |
| WO2010056767A1 (en) | 2010-05-20 |
| US20150182528A1 (en) | 2015-07-02 |
| CN105037323A (zh) | 2015-11-11 |
| WO2010056767A8 (en) | 2010-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ592741A (en) | Thiochromene derivatives as hif hydroxylase inhibitors | |
| TN2012000413A1 (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
| MY150787A (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes | |
| TNSN08367A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2011138751A3 (en) | Heterocyclic derivatives as alk inhibitors | |
| WO2007097931A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2007136603A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| MY160066A (en) | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | |
| MY155836A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| MY160357A (en) | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators | |
| MX2009006630A (es) | Derivados de 4-imidazolil-1,2,3,4-tetrahidro-quinola y su uso como inhibidores de aldosterona / 11-beta-hidroxilasa. | |
| NO20085068L (no) | Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter | |
| IL198979A (en) | Enzyme inhibitors diacylglycerol o-acetyltransferase type 1 | |
| WO2008001195A3 (en) | Novel processes for the preparation of dpp iv inhibitors | |
| TN2009000287A1 (en) | Cyclized derivatives as eg-5inhibitors | |
| MX2009000420A (es) | Derivados de isoindolina para el tratamiento de arritmias. | |
| MX2012006822A (es) | 1,7-diazacarbazoles y metodos de uso. | |
| WO2011047055A8 (en) | Novel mek inhibitors, useful in the treatment of diseases | |
| PH12022551282A1 (en) | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | |
| MX2025011346A (es) | Compuestos de quinolinona amida y usos de los mismos | |
| MX2011010691A (es) | Derivados de imidazolidin-2,4-diona y su uso como un medicamento. | |
| WO2010038948A3 (en) | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders | |
| MX2024015882A (es) | Derivados de 3-(sulfonil o sulfonimidoil)prop-2-en-1-il]-2-oxo-1,2-dihidropiridina-3-carboxamida | |
| MX2022006370A (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso. | |
| PT1896416E (pt) | Heterociclos substituídos, sua utilização como medicamentos e preparações farmacêuticas que os compreendem |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 NOV 2016 BY CPA GLOBAL Effective date: 20131101 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2017 BY CPA GLOBAL Effective date: 20160930 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2018 BY CPA GLOBAL Effective date: 20170929 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2019 BY CPA GLOBAL Effective date: 20181004 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2020 BY CPA GLOBAL Effective date: 20190926 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2021 BY CPA GLOBAL Effective date: 20201008 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2022 BY CPA GLOBAL Effective date: 20210930 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 NOV 2023 BY CPA GLOBAL Effective date: 20220930 |
|
| LAPS | Patent lapsed |